<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>353-MICONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MICONAZOLE" rxcui="6932">
<ATC code="A01AB09" />
<ATC code="A07AC01" />
<ATC code="D01AC02" />
<ATC code="G01AF04" />
<ATC code="J02AB01" />
<ATC code="S02AA13" />
<ATC code="D01AC52" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Unpredictable hemorrhages, possibly serious</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>353-MICONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MICONAZOLE" rxcui="6932">
<ATC code="A01AB09" />
<ATC code="A07AC01" />
<ATC code="D01AC02" />
<ATC code="G01AF04" />
<ATC code="J02AB01" />
<ATC code="S02AA13" />
<ATC code="D01AC52" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="HALOFANTRINE" rxcui="50749">
<ATC code="P01BX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If this is possible, interrupt the azole antifungal. If administering these substances together cannot be avoided, testing before hand of the QT and EKG monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>353-MICONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MICONAZOLE" rxcui="6932">
<ATC code="A01AB09" />
<ATC code="A07AC01" />
<ATC code="D01AC02" />
<ATC code="G01AF04" />
<ATC code="J02AB01" />
<ATC code="S02AA13" />
<ATC code="D01AC52" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin which can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical monitoring. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>353-MICONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MICONAZOLE" rxcui="6932">
<ATC code="A01AB09" />
<ATC code="A07AC01" />
<ATC code="D01AC02" />
<ATC code="G01AF04" />
<ATC code="J02AB01" />
<ATC code="S02AA13" />
<ATC code="D01AC52" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>353-MICONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MICONAZOLE" rxcui="6932">
<ATC code="A01AB09" />
<ATC code="A07AC01" />
<ATC code="D01AC02" />
<ATC code="G01AF04" />
<ATC code="J02AB01" />
<ATC code="S02AA13" />
<ATC code="D01AC52" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BLOOD GLUCOSE LOWERING SULFONAMIDES" code="A10BB" /></DRUG2>
<DESCRIPTION>With the miconazole by general route or oral gel: increase of the hypoglycemic effect with possible onset of hypoglycemic manifestations, even coma</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
</INTERACTIONS>
